Human leukocyte antigen-G (HLA-G), a novel immune checkpoint, exhibits restricted physiologic expression but is broadly expressed in various tumors, conferring systemic immune suppressive functions via different types of immune inhibitory receptors, and is associated with a poor prognosis for patients with cancer, making it an attractive tumor-site-agnostic candidate target for cancer immunotherapy. The gene discussed is HLA-G; the disease is cancer.